0
selected
-
1.
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Li, Z, Liu, Z, Wu, Y, Li, H, Sun, Z, Han, C, Zhang, X, Zhang, J
Thoracic cancer. 2021;(21):2838-2848
Abstract
BACKGROUND To investigate the efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC) through pooling of open published data. METHODS The electronic databases of Medline (1960-2021.5), Cochrane central register of controlled trials (CENTRAL), EMBASE(1980-2021.5) and Wan fang (1986-2021.5) were systematically searched by two reviewers to identify the relevant clinical trials related to the above subject. The objective response rate (ORR), disease control rate (DCR) and drug relevant adverse reactions were pooled and demonstrated by risk ratio (RR) and 95% confidence interval (95% CI). The statistical heterogeneity across studies was assessed by I-square test. The publication bias was evaluated by Egger's line regression test and demonstrated by Begg's funnel plot. RESULTS Eleven prospective studies were included in the meta-analysis. The pooled results indicated that the ORR (RR = 1.62, 95% CI: 1.32-2.00, p < 0.05) and DCR (RR = 1.29, 95% CI: 1.18-1.41, p < 0.05) of apatinib alone or apatinib plus paclitaxel/docetaxel was significantly higher than that of the paclitaxel/docetaxel group for advanced NSCLC, respectively. The drug-related adverse reaction was not statistically different between apatinib alone or apatinib plus paclitaxel/docetaxel with regard to the hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia and leukocytopenia (pall > 0.05) except for hypertension (RR = 3.60, 95% CI: 1.26-10.31, p < 0.05). Subgroup analysis also indicated that the hypertension and hand-foot syndrome in apatinib + paclitaxel/docetaxel were higher than that of the paclitaxel/docetaxel group with a statistical difference (p < 0.05). CONCLUSIONS Apatinib alone or apatinib plus paclitaxel/docetaxel was superior to paclitaxel/docetaxel for ORR and DCR. However, combined treatment with apatinib appears to increase the risk of a patient developing an adverse reaction, especially hypertension and hand-foot syndrome.
-
2.
The Association Between VDR and GC Polymorphisms and Lung Cancer Risk: A Systematic Review and Meta-Analysis.
Duan, GQ, Zheng, X, Li, WK, Zhang, W, Li, Z, Tan, W
Genetic testing and molecular biomarkers. 2020;(5):285-295
Abstract
Background: Lung cancer is the leading cause of cancer-related deaths worldwide, imposing an enormous economic burden on society. Several studies have identified a link between the genetic polymorphisms in vitamin D pathways and lung cancer risk; however, the results remain inconclusive. The aim of this study was to estimate the effect of polymorphisms in the vitamin D receptor (VDR) and GC genes on lung cancer risk. Methods: Eligible case-control studies published between January 2000 and December 2018 were searched and studied. The pooled odds ratio and its 95% confidence interval were used to estimate the effect. Results: Fifteen articles that included 4732 lung cancer patients and 4337 controls were identified for this study. Our results demonstrated that the VDR Bsm1 polymorphism (p < 0.05) and the TC and TT+TC genotypes of the Cdx2 polymorphism (p < 0.05) were protective factors for avoiding lung cancer incidence, while the T allele and the TT genotype of Taq1 polymorphism (p < 0.05) were risk factors for lung cancer. Ethnicity-based subgroup analyses indicated that the AA genotype of both the Apa1 and the Bsm1 polymorphisms decreased lung cancer risk in Asians, while Fok1 and Taq1 polymorphisms increased lung cancer risk in Asians. Subgroup analysis by cancer subtypes showed that certain alleles and genotypic structures of the Bsm1, Fok1, Taq1, and rs7041 were associated with nonsmall-cell lung cancer risk. Subgroup analysis by smoking status showed that the interaction between the TT genotype of Taq1 and smoking increased the risk of lung cancer. Subgroup analysis with regard to gender showed that the AA+Aa genotype of Apa1 decreased lung cancer risk in male patients. Conclusions: Our results suggest that the Bsm1 and Cdx2 polymorphisms decreased lung cancer risk, while the Taq1 polymorphism increased lung cancer risk. Moreover, the AA genotype of the Apa1 and Bsm1 variants were protective factors in Asian populations, whereas the Fok1 and Taq1 polymorphisms were risk factors for lung cancer in Asian populations. Future case-control studies with different ethnicities are still needed to generalize these associations.
-
3.
[Effects of extracts of Prunella Vulgaris L. on proteome of human lung adenocarcinoma cell line A549].
Wang, P, Li, Z, Fu, L, Zhu, J, Wu, X, Wang, Z, Zhang, L
Zhonghua yi xue za zhi. 2014;(28):2216-21
Abstract
OBJECTIVE To explore the effect of extracts of Prunella vulgaris L.on proteome of human lung adenocarcinoma cell line A549 by two-dimensional electrophoresis and mass spectrometry and elucidate the mechanism of anti-lung adenocarcinom effect of Prunella vulgaris L.at the level of proteome. METHODS The proliferative activity of human lung adenocarcinoma cell line A549 was evaluated by methyl thiazolyl tetrazolium (MTT) colorimetric assay. According to the difference of culture medium, all subjects were divided into the experimental group with culture medium of extracts of Prunella vulgaris L. (300 µg/ml) and the control group with culture medium of DMSO (0.3%). Proteins were isolated by two-dimensional electrophoresis and proteomic maps acquired by silver staining. And proteomic analysis was processed by Image Master 2D Quant Platinum 6.0. The proteins with > 2-fold differences were used to analyze by mass spectrometry and confirmed by Western blot. RESULTS The expressions of inositol 1, 4, 5-triphosphate receptor-interacting protein-like 2 precursor, heat shock cognate protein 70, serine-threonine kinase receptor-associated protein, tropomyosin 2(β) isoform 1, cyclin B3, MED12L protein and macrophin 1 isoform 2 were higher in experimental group than those in control group (ratio (medicial/normal) 2.051 93, 1 000 001, 2.203 08, 5.042 01, 15.178 00, 1 000 001, 1 000 001) . And the expressions of enolase 1, M2-type pyruvate kinase, heat shock protein 27, Rho GDP-dissociation inhibitor 1, heat shock protein β1, TapasinERP57 heterodimer chain A, inorganic pyrophosphatase and mitochondrial Cysteinyl-tRNA synthetase 2 (putative) were lower in experimental group than those in control group (ratio (medicial/normal) 0.485 18, 0.491 53, 0.465 43, 0.454 71, 0.499 34, 0.450 36, 0.494 62, 0.437 33). CONCLUSIONS The extracts of Prunella vulgaris L.have multi-target and multi-pathway effects on anti-lung adenocarcinoma. And its possible mechanisms may be due to the regulation of steady state of calcium ion, cell cycle and its steady state and the inhibition of tumor cell proliferation and metastasis.
-
4.
Tea consumption and lung cancer risk: a meta-analysis of case-control and cohort studies.
Wang, L, Zhang, X, Liu, J, Shen, L, Li, Z
Nutrition (Burbank, Los Angeles County, Calif.). 2014;(10):1122-7
Abstract
OBJECTIVE Recent epidemiologic studies, especially cohort and case-control studies, have yielded inconsistent findings regarding the association between tea consumption and risk for lung cancer. The aim of this study was to assess a potential relationship between tea consumption and the incidence of lung cancer worldwide. METHODS A systematic literature search of PubMed, Web of Science, the Cochrane Library, Google Scholar, the Chinese Biomedical Database, and Wanfang Database was conducted from 1966 to January 2014 by two investigators. All cohort studies and case-control studies that evaluated the association of tea and lung cancer were included. Summary relative risks (RR) and the corresponding 95% confidence intervals (CIs) were calculated using a random-effects model. Quality assessments were performed using the Newcastle-Ottawa Scale. Heterogeneity was assessed using the Q and I(2) tests, and the source of heterogeneity was detected by meta-regression analysis. Publication bias was evaluated with Egger's regression symmetry test. Subgroup analyses and sensitivity analysis were performed. RESULTS Thirty-eight lung cancer studies (26 case-control studies and 12 cohort studies) with 59,041 cases and 396,664 controls were included. Overall tea consumption was significantly associated with decreased risk for lung cancer (RR, 0.78; 95% CI, 0.70-0.87). Subgroup analyses showed that tea consumption was associated with reduced risk for lung cancer in women (RR, 0.76; 95% CI, 0.62-0.93), case-control studies (RR 0.72; 95% CI 0.63-0.83), Western studies (RR, 0.85; 95% CI, 0.75-0.97), and studies in China and Japan (RR, 0.74; 95% CI, 0.62-0.88). Both green tea (RR, 0.75; 95% CI, 0.62-0.91) and black tea (RR, 0.82; 95% CI, 0.71-0.94) were significantly associated with reduced lung cancer risk. No significant association was found in men or in cohort studies. CONCLUSION Tea consumption may offer some protection against lung cancer.
-
5.
[A meta analysis of radiosensitivity on non-small cell lung cancer by metronidazole amino acidum natrium].
Ren, W, Li, Z, Mi, D, Yang, K, Tian, J, Zhang, Z
Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2012;(6):340-7
Abstract
BACKGROUND AND OBJECTIVE The efficacy and safety of radiosensitivity on non-small cell lung cancer (NSCLC) using metronidazole amino acidum natrium (CMNa) are yet to be proven. This study evaluates the efficacy and safety of radiosensitivity on NSCLC by CMNa to provide references for further clinical practice and research. METHODS Relevant randomized controlled trials (RCTs) were obtained from the Cochrane library, Pubmed, EMbase, CBM, CNKI, VIP, and Wan Fang databases. Dates were searched through other means. RCTs of radiosensitivity on NSCLC by CMNa were included. The data included in the study were evaluated and analyzed using the Cochrane Collaboration's RevMan 5.1 software. RESULTS A total of 21 RCTs were included. The results of the meta-analyses showed that the total effective rate of the test group that received CMNa plus radiotherapy was higher than that of the control group that received radiotherapy alone (OR=3.29, 95%CI: 2.47-4.39, P<0.000,01) or radiotherapy plus placebo (OR=3.65, 95%CI: 2.25-5.92, P<0.000,01), respectively. No significant differences were found in the quality of life between one and two-year survival rates (P>0.05). No significant differences were found among radiation pneumonitis, radiation esophagitis, hematological toxicity, and cardiotoxicity (P>0.05). CONCLUSIONS CMNa plus radiotherapy elicit beneficial effects in the treatment of NSCLC and produce fewer adverse effects. Therefore, this technique can be recommended and applied in clinics.